CD40LG and COVID-19: In comparison to the commercial ELISA kits, the in-house assays demonstrated higher sensitivities for detection of serum antibodies in COVID-19 confirmed cases where 70.0% (n = 35/50), 84.0% (n = 42/50), 88.0% (n = 44/50), and 82.0% (n = 41/50) were detected as seropositive by RBD-IgG, RBD-IgM, NC-IgG, and NC-IgM assays, respectively (Table 3).